Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02427451 · ClinicalTrials.gov registry record · Phase 1
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
A Phase 1 study of Chronic Lymphocytic Leukemia and Refractory Chronic Lymphocytic Leukemia, sponsored by Kerry Rogers.
- Active
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT02427451 is a Phase 1 study of Chronic Lymphocytic Leukemia and Refractory Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by Kerry Rogers. The registered enrollment target is 87 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02427451, a Phase 1 study of Chronic Lymphocytic Leukemia and Refractory Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Kerry Rogers.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase Ib/II trial studies the best dose and safety of Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib and to see how well they work in treating patients with chronic lymphocytic leukemia that has returned (relapsed), does not respond to treatment (refractory), or is previously untreated. Bcl-2 inhibitor GDC-0199 and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may block cancer growth in different ways by targeting certain cells. Giving Bcl-2 inhibitor GDC-0199 together with obinutuzumab and ibrutinib may be a better treatment for chronic lymphocytic leukemia.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Obinutuzumab
- DRUG Ibrutinib
- OTHER Pharmacological Study
- DRUG Bcl-2 Inhibitor GDC-0199
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2015-08-03 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02427451
The ClinicalTrials.gov registry entry for NCT02427451 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (52% lower). The listed sponsor is Kerry Rogers, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02427451 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02427451 about?
NCT02427451 is a clinical study titled "Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia". This phase Ib/II trial studies the best dose and safety of Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib and to see how well they work in treating patients with chronic lymphocytic leukemia that has returned (relapsed), does not respond to treatment (refractory), or is prev...
What is the current status of trial NCT02427451?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2015-08-03. Estimated completion is 2026-04-15.
What conditions does trial NCT02427451 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT02427451?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Obinutuzumab (BIOLOGICAL), Ibrutinib (DRUG), Pharmacological Study (OTHER), Bcl-2 Inhibitor GDC-0199 (DRUG).
Who is sponsoring clinical trial NCT02427451?
This trial is sponsored by Kerry Rogers, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02427451 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.